\-\ Texto\\:\\ \ \(0\)\
\-\ he\\ is\\ at\\ average\\ risk\\ for\\ colonic\\ polyps\\ and\\ colon\\ cancer\\.\\ he\\ states\\ he\\ is\\ doing\\ well\\ and\\ is\\ in\\ his\\ normal\\ state\\ of\\ health\\.\\ he\\ denies\\ change\\ in\\ bowel\\ movement\\,\\ weight\\ loss\\,\\ or\\ blood\\ in\\ his\\ stool\\.\\ he\\ has\\ no\\ history\\ of\\ rectal\\ bleeding\\,\\ hematochezia\\,\\ or\\ melena\\.\\ he\\ is\\ without\\ positive\\ stool\\ guaiac\\ test\\ or\\ history\\ of\\ iron\\ deficiency\\ anemia\\ within\\ the\\ past\\ 6\\ months\\.\\ the\\ patient\\ has\\ not\\ had\\ prior\\ evaluations\\ for\\ colon\\ cancer\\ screening\\.\\ his\\ past\\ medical\\ history\\ and\\ family\\ history\\ is\\ unremarkable\\ for\\ adenomatous\\ polyps\\,\\ colorectal\\ cancer\\,\\ inflammatory\\ bowel\\ disease\\,\\ hnpcc\\ or\\ faps\\.\ \(0\)\
\-\ polyp\\ was\\ biopsed\\ and\\ patient\\ received\\ appropriate\\ follow\\-up\\ care\\.\\ no\\ other\\ information\\ was\\ documented\ \(0\)\
\-\ a\\ still\\ image\\ from\\ the\\ 3\\-dimensional\\ endoluminal\\ fly\\-through\\ of\\ the\\ rectum\\ reveals\\ a\\ raised\\,\\ broad\\ based\\,\\ unilobular\\ lesion\\ with\\ smooth\\ contours\\ that\\ projects\\ into\\ the\\ lumen\\ of\\ the\\ rectum\\.\\ non\\-contrast\\ ct\\ cuts\\ in\\ the\\ cross\\-sectional\\ and\\ axial\\ views\\ from\\ the\\ same\\ level\\ of\\ the\\ endoluminal\\ still\\ image\\ confirms\\ the\\ presence\\ and\\ location\\ of\\ the\\ lesion\\.\\ the\\ lesion\\ is\\ a\\ well\\-demarcated\\ ovoid\\ mass\\ projecting\\ in\\ the\\ posterior\\ lumen\\ of\\ the\\ rectum\\ with\\ a\\ broad\\ base\\.\\ \\ attenuation\\ homogenous\\ to\\ surrounding\\ soft\\ tissue\\.\ \(0\)\
\-\ \\Â\\»\\ multimedia\\ links\\:\ \(0\)\
\-\ \\â\\€\\¢\\ http\\:\\/\\/rad\\.usuhs\\.mil\\/medpix\\/multimedia\\_files\\/ocvideo\\.mpg\ \(1\)\
\-\ \\â\\€\\¢\\ http\\:\\/\\/rad\\.usuhs\\.mil\\/medpix\\/multimedia\\_files\\/vcvideo\\.mpg\ \(1\)\
\-\ tubulovillous\\ adenoma\ \(1\)\
\-\ polyp\ \(200\)\
\-\ colon\\ cancer\ \(55\)\
\-\ lipoma\ \(291\)\
\-\ residual\\ fecal\\ matter\\ \\(untagged\\ feces\\)\ \(1\)\
\-\ foreign\\ body\ \(86\)\
\-\ lymphoma\ \(373\)\
\-\ this\\ 59\\ yo\\ man\\ presents\\ to\\ the\\ clinic\\ for\\ enrollment\\ in\\ the\\ virtual\\ colonoscopy\\ screening\\ protocol\\.\ \(0\)\
\-\ although\\ not\\ all\\ colon\\ polyps\\ will\\ develop\\ into\\ colon\\ cancer\\,\\ almost\\ all\\ sporadic\\ colon\\ cancer\\ arises\\ from\\ mucosal\\ colonic\\ polyps\\.\\ histology\\ of\\ the\\ polyps\\ is\\ a\\ critical\\ parameter\\ determining\\ malignant\\ potential\\ with\\ virtually\\ all\\ colon\\ cancers\\ believed\\ to\\ arise\\ from\\ adenomas\\.\\ killing\\ approximately\\ 60\\,000\\ americans\\ per\\ year\\,\\ colon\\ cancer\\ is\\ the\\ second\\ leading\\ cause\\ of\\ cancer\\-related\\ mortality\\ in\\ the\\ united\\ states\\.\\ \\ clinical\\ trials\\ have\\ shown\\ that\\ the\\ incidence\\ and\\ mortality\\ from\\ colon\\ cancer\\ can\\ decrease\\ with\\ early\\ detection\\ and\\ removal\\ of\\ premalignant\\ adenomatous\\ polyps\\.\\ appropriate\\ colon\\ cancer\\ screening\\,\\ therefore\\ is\\ important\\ to\\ prevent\\ colon\\ cancer\\ and\\ is\\ recommended\\ for\\ all\\ adults\\ over\\ 50\\ years\\ old\\.\\ \\ nonetheless\\,\\ despite\\ this\\ evidence\\,\\ less\\ than\\ one\\ fourth\\ of\\ the\\ eligible\\ population\\ in\\ the\\ united\\ states\\ participates\\ in\\ any\\ method\\ of\\ colon\\ cancer\\ screening\\.\ \(0\)\
\-\ currently\\ conventional\\ colonography\\ is\\ the\\ primary\\ screening\\ test\\ used\\ to\\ detect\\ colonic\\ polyps\\ and\\ cancers\\.\\ many\\ barriers\\ prevent\\ individuals\\ from\\ receiving\\ colonoscopy\\,\\ including\\ expense\\,\\ invasiveness\\,\\ patient\\ discomfort\\,\\ need\\ for\\ sedation\\ and\\ analgesia\\,\\ and\\ test\\ risks\\.\\ the\\ introduction\\ of\\ virtual\\ colonoscopy\\ \\(ct\\ colonography\\)\\ in\\ 1994\\ by\\ vining\\ was\\ to\\ maintain\\ the\\ desirable\\ features\\ of\\ colonoscopy\\ of\\ ease\\ of\\ lesion\\ detection\\ while\\ avoiding\\ the\\ undesirable\\ features\\ as\\ described\\ above\\.\\ since\\ 1994\\,\\ there\\ has\\ been\\ significant\\ progress\\ and\\ development\\ of\\ virtual\\ colonoscopy\\,\\ making\\ the\\ procedure\\ a\\ viable\\ alternative\\ in\\ screening\\ the\\ general\\ population\\ for\\ colon\\ cancer\\.\\ currently\\,\\ various\\ institutions\\ worldwide\\ perform\\ virtual\\ colonoscopy\\ on\\ an\\ elective\\ basis\\.\\ with\\ its\\ many\\ advantages\\,\\ this\\ technique\\ may\\ encourage\\ more\\ adults\\ to\\ seek\\ testing\\.\\ some\\ of\\ these\\ advantages\\ include\\:\\ lack\\ of\\ sedation\\,\\ minimal\\ invasiveness\\,\\ rare\\ test\\ complications\\,\\ detection\\ of\\ extracolonic\\ abnormalities\\,\\ and\\ convenience\\,\\ taking\\ 15\\ minutes\\ or\\ less\\.\\ however\\,\\ unlike\\ conventional\\ colonoscopy\\,\\ virtual\\ colonoscopy\\ is\\ not\\ therapeutic\\ and\\ requires\\ a\\ follow\\-up\\ procedure\\ with\\ conventional\\ colonoscopy\\ for\\ identified\\ polyps\\.\\ \ \(0\)\
\-\ virtual\\ colonoscopy\\ is\\ currently\\ under\\ intense\\ analysis\\ in\\ order\\ to\\ establish\\ the\\ procedure\\ as\\ a\\ primary\\ screening\\ method\\.\\ there\\ have\\ been\\ three\\ recent\\ multicenter\\ virtual\\ colonoscopy\\ clinical\\ trials\\ published\\,\\ which\\ report\\ widely\\ divergent\\ results\\ primarily\\ due\\ to\\ differences\\ in\\ ct\\ technology\\,\\ adjunctive\\ techniques\\,\\ ct\\ colonographic\\ interpretation\\,\\ and\\ study\\ design\\.\\ this\\ patient\\ was\\ in\\ a\\ prospective\\ multi\\-center\\ trial\\ published\\ in\\ 2003\\ by\\ pickhardt\\ et\\ al\\,\\ which\\ evaluated\\ the\\ use\\ of\\ virtual\\ colonoscopy\\ as\\ a\\ screening\\ tool\\ compared\\ with\\ traditional\\ colonoscopy\\.\\ in\\ this\\ study\\,\\ researchers\\ performed\\ both\\ conventional\\ and\\ virtual\\ colonoscopy\\ in\\ 1\\,233\\ asymptomatic\\ adults\\,\\ 97\\.4\\ percent\\ of\\ whom\\ were\\ at\\ average\\ risk\\ of\\ having\\ colonic\\ polyps\\.\\ pickhardt\\ and\\ associates\\ reported\\ a\\ sensitivity\\ of\\ 93\\.8\\%\\ for\\ polyps\\ at\\ least\\ 10\\ mm\\ in\\ diameter\\,\\ 93\\.9\\%\\ for\\ polyps\\ at\\ least\\ 8mm\\ in\\ diameter\\,\\ and\\ 88\\.7\\%\\ for\\ polyps\\ at\\ least\\ 6mm\\ in\\ diameter\\.\\ subsequently\\,\\ for\\ conventional\\ colonoscopy\\,\\ the\\ sensitivity\\ was\\ 87\\.5\\%\\,\\ 91\\.5\\%\\,\\ and\\ 92\\.3\\%\\ respectively\\ for\\ these\\ three\\ categories\\ of\\ polyp\\ size\\.\\ in\\ this\\ study\\,\\ virtual\\ colonoscopy\\ also\\ detected\\ two\\ malignant\\ polyps\\ while\\ conventional\\ colonoscopy\\ missed\\ one\\ of\\ them\\.\\ with\\ these\\ results\\,\\ pickhardt\\ et\\ al\\ demonstrated\\ that\\ virtual\\ colonoscopy\\ is\\ an\\ excellent\\ screening\\ test\\ for\\ colonic\\ polyps\\ and\\ rivals\\ conventional\\ colonoscopy\\.\\ furthermore\\,\\ a\\ metaanalysis\\ on\\ the\\ accuracy\\ of\\ virtual\\ colonoscopy\\ by\\ sosna\\ et\\ al\\ in\\ 2003\\ revealed\\ that\\ virtual\\ colonoscopy\\ is\\ an\\ accurate\\ tool\\ for\\ detecting\\ clinically\\ important\\ colorectal\\ polyps\\,\\ that\\ is\\,\\ polyps\\ that\\ are\\ greater\\ or\\ equal\\ to\\ 10\\ mm\\.\\ \\ the\\ future\\ of\\ virtual\\ colonoscopy\\ is\\ promising\\.\\ when\\ the\\ accuracy\\,\\ reliability\\,\\ and\\ cost\\-effectiveness\\ of\\ virtual\\ colonoscopy\\ is\\ established\\ in\\ detecting\\ polyps\\ and\\ cancers\\,\\ this\\ method\\ has\\ the\\ potential\\ to\\ improve\\ patient\\ participation\\ in\\ screening\\ programs\\ and\\ help\\ decrease\\ the\\ impact\\ of\\ colorectal\\ cancer\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ colonoscopy\\:\\ 0\\.12715983551217325\ \(0\)\
\-\ virtual\\:\\ 0\\.1039451618598386\ \(0\)\
\-\ polyps\\:\\ 0\\.09758852382714182\ \(0\)\
\-\ colon\\:\\ 0\\.044646557558612056\ \(0\)\
\-\ cancer\\:\\ 0\\.04048686079461413\ \(0\)\
\-\ screening\\:\\ 0\\.04041058125197724\ \(0\)\
\-\ conventional\\:\\ 0\\.03760153611186324\ \(0\)\
\-\ pickhardt\\:\\ 0\\.02931990606640742\ \(0\)\
\-\ colonic\\:\\ 0\\.02581283448229948\ \(0\)\
\-\ colorectal\\:\\ 0\\.02054255352888439\ \(0\)\
\-\ test\\:\\ 0\\.020236876108885724\ \(0\)\
\-\ invasiveness\\:\\ 0\\.019546604044271616\ \(0\)\
\-\ method\\:\\ 0\\.01769072348946791\ \(0\)\
\-\ cancers\\:\\ 0\\.01713511123449064\ \(0\)\
\-\ detection\\:\\ 0\\.01651453710284847\ \(0\)\
\-\ rectum\\:\\ 0\\.015872950630150602\ \(0\)\
\-\ he\\:\\ 0\\.015859339303989042\ \(0\)\
\-\ endoluminal\\:\\ 0\\.015573744910728255\ \(0\)\
\-\ colonography\\:\\ 0\\.015573744910728255\ \(0\)\
\-\ advantages\\:\\ 0\\.015573744910728255\ \(0\)\
\-\ \\,\\:\\ 0\\.015306223216609375\ \(0\)\
\-\ adults\\:\\ 0\\.014505003750708392\ \(0\)\
\-\ tool\\:\\ 0\\.01444109386024934\ \(0\)\
\-\ least\\:\\ 0\\.014244741455032956\ \(0\)\
\-\ published\\:\\ 0\\.014229763084629995\ \(0\)\
\-\ sedation\\:\\ 0\\.014036833202169618\ \(0\)\
\-\ trials\\:\\ 0\\.013695035685922926\ \(0\)\
\-\ states\\:\\ 0\\.013369383187482563\ \(0\)\
\-\ \\%\\:\\ 0\\.013259341685228432\ \(0\)\
\-\ 1994\\:\\ 0\\.01279599996949684\ \(0\)\
\-\ adenomatous\\:\\ 0\\.012692851376071358\ \(0\)\
\-\ accuracy\\:\\ 0\\.012692851376071358\ \(0\)\
\-\ detecting\\:\\ 0\\.01249992149361098\ \(0\)\
\-\ for\\:\\ 0\\.012124858347716991\ \(0\)\
\-\ al\\:\\ 0\\.012048430952581889\ \(0\)\
\-\ diameter\\:\\ 0\\.011957303543973969\ \(0\)\
\-\ procedure\\:\\ 0\\.011903801977172558\ \(0\)\
\-\ united\\:\\ 0\\.011663348919017925\ \(0\)\
\-\ et\\:\\ 0\\.011632145554730427\ \(0\)\
\-\ currently\\:\\ 0\\.011262215504474692\ \(0\)\
\-\ is\\:\\ 0\\.011220880278187429\ \(0\)\
\-\ in\\:\\ 0\\.011212343152290596\ \(0\)\
\-\ average\\:\\ 0\\.011057377001058544\ \(0\)\
\-\ polyp\\:\\ 0\\.010785531497527872\ \(0\)\
\-\ all\\:\\ 0\\.010718064254684216\ \(0\)\
\-\ sensitivity\\:\\ 0\\.010701850060758812\ \(0\)\
\-\ stool\\:\\ 0\\.010431584389785337\ \(0\)\
\-\ mortality\\:\\ 0\\.01032513379291979\ \(0\)\
\-\ population\\:\\ 0\\.009886495781101788\ \(0\)\
\-\ broad\\:\\ 0\\.009830358734573429\ \(0\)\
\-\ that\\:\\ 0\\.009818053626777096\ \(0\)\
\-\ faps\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ biopsed\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ 3\\-dimensional\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ fly\\-through\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ unilobular\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ links\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ \\/\\/rad\\.usuhs\\.mil\\/medpix\\/multimedia\\_files\\/ocvideo\\.mpg\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ \\/\\/rad\\.usuhs\\.mil\\/medpix\\/multimedia\\_files\\/vcvideo\\.mpg\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ \\-colon\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ untagged\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ \\-foreign\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ enrollment\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ 60\\,000\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ cancer\\-related\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ participates\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ expense\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ vining\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ undesirable\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ encourage\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ extracolonic\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ convenience\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ colonographic\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ multi\\-center\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ 1\\,233\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ 88\\.7\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ 87\\.5\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ 91\\.5\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ rivals\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ metaanalysis\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ sosna\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ cost\\-effectiveness\\:\\ 0\\.009773302022135808\ \(0\)\
\-\ 2003\\:\\ 0\\.009520465292499907\ \(0\)\
\-\ prevent\\:\\ 0\\.009403120721647706\ \(0\)\
\-\ study\\:\\ 0\\.009351323803303634\ \(0\)\
\-\ lumen\\:\\ 0\\.00912425290060772\ \(0\)\
\-\ potential\\:\\ 0\\.00912425290060772\ \(0\)\
\-\ still\\:\\ 0\\.009025690234153543\ \(0\)\
\-\ hnpcc\\:\\ 0\\.00900484616785649\ \(0\)\
\-\ \\-polyp\\:\\ 0\\.00900484616785649\ \(0\)\
\-\ \\-lipoma\\:\\ 0\\.00900484616785649\ \(0\)\
\-\ \\-residual\\:\\ 0\\.00900484616785649\ \(0\)\
\-\ killing\\:\\ 0\\.00900484616785649\ \(0\)\
\-\ premalignant\\:\\ 0\\.00900484616785649\ \(0\)\
\-\ multicenter\\:\\ 0\\.00900484616785649\ \(0\)\
\-\ design\\:\\ 0\\.00900484616785649\ \(0\)\
\-\ 97\\.4\\:\\ 0\\.00900484616785649\ \(0\)\
\-\ associates\\:\\ 0\\.00900484616785649\ \(0\)\
\-\ 93\\.8\\:\\ 0\\.00900484616785649\ \(0\)\
\-\ 93\\.9\\:\\ 0\\.00900484616785649\ \(0\)\
\-\ 92\\.3\\:\\ 0\\.00900484616785649\ \(0\)\
\-\ appropriate\\:\\ 0\\.008931323018147344\ \(0\)\
\-\ decrease\\:\\ 0\\.008670163293853811\ \(0\)\
\-\ multimedia\\:\\ 0\\.008555328309643445\ \(0\)\
\-\ nonetheless\\:\\ 0\\.008555328309643445\ \(0\)\
\-\ barriers\\:\\ 0\\.008555328309643445\ \(0\)\
\-\ promising\\:\\ 0\\.008555328309643445\ \(0\)\
\-\ important\\:\\ 0\\.008511717697441072\ \(0\)\
\-\ from\\:\\ 0\\.008424184344706513\ \(0\)\
\-\ tubulovillous\\:\\ 0\\.00823639031357717\ \(0\)\
\-\ parameter\\:\\ 0\\.00823639031357717\ \(0\)\
\-\ ease\\:\\ 0\\.00823639031357717\ \(0\)\
\-\ programs\\:\\ 0\\.00823639031357717\ \(0\)\
\-\ his\\:\\ 0\\.008191426921220395\ \(0\)\
\-\ features\\:\\ 0\\.007995636964800615\ \(0\)\
\-\ feces\\:\\ 0\\.007989002784403988\ \(0\)\
\-\ desirable\\:\\ 0\\.007989002784403988\ \(0\)\
\-\ divergent\\:\\ 0\\.007989002784403988\ \(0\)\
\-\ researchers\\:\\ 0\\.007989002784403988\ \(0\)\
\-\ many\\:\\ 0\\.007787613117311358\ \(0\)\
\-\ participation\\:\\ 0\\.007786872455364128\ \(0\)\
\-\ lesion\\:\\ 0\\.007718648452330176\ \(0\)\
\-\ results\\:\\ 0\\.007648652791451545\ \(0\)\
\-\ eligible\\:\\ 0\\.0076159736972407814\ \(0\)\
\-\ introduction\\:\\ 0\\.0076159736972407814\ \(0\)\
\-\ avoiding\\:\\ 0\\.0076159736972407814\ \(0\)\
\-\ institutions\\:\\ 0\\.0076159736972407814\ \(0\)\
\-\ technology\\:\\ 0\\.0076159736972407814\ \(0\)\
\-\ adjunctive\\:\\ 0\\.0076159736972407814\ \(0\)\
\-\ americans\\:\\ 0\\.007467934459297851\ \(0\)\
\-\ worldwide\\:\\ 0\\.007467934459297851\ \(0\)\
\-\ this\\:\\ 0\\.007458936245231631\ \(0\)\
\-\ these\\:\\ 0\\.007396379241544923\ \(0\)\
\-\ analgesia\\:\\ 0\\.007337354597151085\ \(0\)\
\-\ whom\\:\\ 0\\.007337354597151085\ \(0\)\
\-\ cuts\\:\\ 0\\.00722054693012467\ \(0\)\
\-\ cross\\-sectional\\:\\ 0\\.00722054693012467\ \(0\)\
\-\ differences\\:\\ 0\\.00722054693012467\ \(0\)\
\-\ reliability\\:\\ 0\\.00722054693012467\ \(0\)\
\-\ http\\:\\ 0\\.007174697556497286\ \(0\)\
\-\ has\\:\\ 0\\.0071161861219258445\ \(0\)\
\-\ evaluations\\:\\ 0\\.007114881542314998\ \(0\)\
\-\ well\\-demarcated\\:\\ 0\\.007018416601084809\ \(0\)\
\-\ mm\\:\\ 0\\.006967173296662983\ \(0\)\
\-\ melena\\:\\ 0\\.0069296774573225734\ \(0\)\
\-\ \\-lymphoma\\:\\ 0\\.0069296774573225734\ \(0\)\
\-\ traditional\\:\\ 0\\.0069296774573225734\ \(0\)\
\-\ risk\\:\\ 0\\.006862985914321699\ \(0\)\
\-\ malignant\\:\\ 0\\.006848493739200224\ \(0\)\
\-\ establish\\:\\ 0\\.006847517842961463\ \(0\)\
\-\ 8mm\\:\\ 0\\.006847517842961463\ \(0\)\
\-\ hematochezia\\:\\ 0\\.006771029071911627\ \(0\)\
\-\ fecal\\:\\ 0\\.006771029071911627\ \(0\)\
\-\ interpretation\\:\\ 0\\.006771029071911627\ \(0\)\
\-\ guaiac\\:\\ 0\\.006699478605018533\ \(0\)\
\-\ or\\:\\ 0\\.006662013851199828\ \(0\)\
\-\ viable\\:\\ 0\\.006632267272627807\ \(0\)\
\-\ contours\\:\\ 0\\.006568898742871767\ \(0\)\
\-\ projects\\:\\ 0\\.006452091075845352\ \(0\)\
\-\ alternative\\:\\ 0\\.006452091075845352\ \(0\)\
\-\ seek\\:\\ 0\\.006452091075845352\ \(0\)\
\-\ categories\\:\\ 0\\.006452091075845352\ \(0\)\
\-\ at\\:\\ 0\\.006417755836095527\ \(0\)\
\-\ less\\:\\ 0\\.006416718413132333\ \(0\)\
\-\ elective\\:\\ 0\\.00639799998474842\ \(0\)\
\-\ three\\:\\ 0\\.006387193410968759\ \(0\)\
\-\ 10\\:\\ 0\\.006387193410968759\ \(0\)\
\-\ adenomas\\:\\ 0\\.006297144354808591\ \(0\)\
\-\ determining\\:\\ 0\\.00624996074680549\ \(0\)\
\-\ widely\\:\\ 0\\.00624996074680549\ \(0\)\
\-\ prospective\\:\\ 0\\.00624996074680549\ \(0\)\
\-\ 6mm\\:\\ 0\\.00620470354667217\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.006164161843551535\ \(0\)\
\-\ accurate\\:\\ 0\\.006161221603043255\ \(0\)\
\-\ sporadic\\:\\ 0\\.0061193808846587245\ \(0\)\
\-\ risks\\:\\ 0\\.0061193808846587245\ \(0\)\
\-\ raised\\:\\ 0\\.006040158086452354\ \(0\)\
\-\ past\\:\\ 0\\.006020397942231561\ \(0\)\
\-\ virtually\\:\\ 0\\.006002573217632309\ \(0\)\
\-\ missed\\:\\ 0\\.006002573217632309\ \(0\)\
\-\ iron\\:\\ 0\\.005966220864170014\ \(0\)\
\-\ unlike\\:\\ 0\\.005966220864170014\ \(0\)\
\-\ trial\\:\\ 0\\.005966220864170014\ \(0\)\
\-\ while\\:\\ 0\\.005961528248009564\ \(0\)\
\-\ bowel\\:\\ 0\\.0059422473012965835\ \(0\)\
\-\ image\\:\\ 0\\.00591837952615876\ \(0\)\
\-\ critical\\:\\ 0\\.005896907829822636\ \(0\)\
\-\ clinical\\:\\ 0\\.005829955210789366\ \(0\)\
\-\ maintain\\:\\ 0\\.005800442888592448\ \(0\)\
\-\ them\\:\\ 0\\.005800442888592448\ \(0\)\
\-\ furthermore\\:\\ 0\\.005800442888592448\ \(0\)\
\-\ established\\:\\ 0\\.005800442888592448\ \(0\)\
\-\ detect\\:\\ 0\\.0057405014015965775\ \(0\)\
\-\ documented\\:\\ 0\\.005683635221566033\ \(0\)\
\-\ projecting\\:\\ 0\\.005683635221566033\ \(0\)\
\-\ arises\\:\\ 0\\.005683635221566033\ \(0\)\
\-\ believed\\:\\ 0\\.005683635221566033\ \(0\)\
\-\ basis\\:\\ 0\\.005683635221566033\ \(0\)\
\-\ techniques\\:\\ 0\\.005656259819581142\ \(0\)\
\-\ doing\\:\\ 0\\.005629544130469101\ \(0\)\
\-\ homogenous\\:\\ 0\\.005629544130469101\ \(0\)\
\-\ histology\\:\\ 0\\.005629544130469101\ \(0\)\
\-\ impact\\:\\ 0\\.005629544130469101\ \(0\)\
\-\ primary\\:\\ 0\\.005612825416620169\ \(0\)\
\-\ individuals\\:\\ 0\\.005528688500529272\ \(0\)\
\-\ the\\:\\ 0\\.005517709810787725\ \(0\)\
\-\ receiving\\:\\ 0\\.005481504892526173\ \(0\)\
\-\ was\\:\\ 0\\.0054782567750204375\ \(0\)\
\-\ technique\\:\\ 0\\.005458645372345756\ \(0\)\
\-\ respectively\\:\\ 0\\.005458645372345756\ \(0\)\
\-\ perform\\:\\ 0\\.005436247692392851\ \(0\)\
\-\ excellent\\:\\ 0\\.0054142935601354455\ \(0\)\
\-\ rectal\\:\\ 0\\.005371648015980462\ \(0\)\
\-\ state\\:\\ 0\\.005350925030379406\ \(0\)\
\-\ progress\\:\\ 0\\.005350925030379406\ \(0\)\
\-\ therapeutic\\:\\ 0\\.0053305823045831785\ \(0\)\
\-\ ct\\:\\ 0\\.0053006813897651574\ \(0\)\
\-\ a\\:\\ 0\\.005276272308008\ \(0\)\
\-\ health\\:\\ 0\\.005252750532218158\ \(0\)\
\-\ making\\:\\ 0\\.005252750532218158\ \(0\)\
\-\ future\\:\\ 0\\.005252750532218158\ \(0\)\
\-\ various\\:\\ 0\\.005234117363352991\ \(0\)\
\-\ history\\:\\ 0\\.0052337673512509245\ \(0\)\
\-\ ovoid\\:\\ 0\\.005215792194892668\ \(0\)\
\-\ to\\:\\ 0\\.005208147663938857\ \(0\)\
\-\ information\\:\\ 0\\.005162566896459895\ \(0\)\
\-\ percent\\:\\ 0\\.005162566896459895\ \(0\)\
\-\ been\\:\\ 0\\.005154755852470047\ \(0\)\
\-\ one\\:\\ 0\\.005134659386498102\ \(0\)\
\-\ deficiency\\:\\ 0\\.0051117802711480404\ \(0\)\
\-\ 59\\:\\ 0\\.00509535556406917\ \(0\)\
\-\ protocol\\:\\ 0\\.00509535556406917\ \(0\)\
\-\ improve\\:\\ 0\\.005047492845815058\ \(0\)\
\-\ confirms\\:\\ 0\\.0050319870343131295\ \(0\)\
\-\ taking\\:\\ 0\\.0050319870343131295\ \(0\)\
\-\ requires\\:\\ 0\\.0050319870343131295\ \(0\)\
\-\ intense\\:\\ 0\\.005016695102902558\ \(0\)\
\-\ \\:\\:\\ 0\\.005012305170690311\ \(0\)\
\-\ detected\\:\\ 0\\.005001611231443823\ \(0\)\
\-\ primarily\\:\\ 0\\.004972045547317259\ \(0\)\
\-\ equal\\:\\ 0\\.004957553217419972\ \(0\)\
\-\ minutes\\:\\ 0\\.004901407172166363\ \(0\)\
\-\ mucosal\\:\\ 0\\.004887803965301823\ \(0\)\
\-\ analysis\\:\\ 0\\.004822184373959994\ \(0\)\
\-\ and\\:\\ 0\\.004789596604848384\ \(0\)\
\-\ patient\\:\\ 0\\.004748292299979978\ \(0\)\
\-\ discomfort\\:\\ 0\\.004748247151677652\ \(0\)\
\-\ order\\:\\ 0\\.004748247151677652\ \(0\)\
\-\ movement\\:\\ 0\\.004736389846670171\ \(0\)\
\-\ by\\:\\ 0\\.00473238659615812\ \(0\)\
\-\ develop\\:\\ 0\\.004724658018144077\ \(0\)\
\-\ need\\:\\ 0\\.004724658018144077\ \(0\)\
\-\ help\\:\\ 0\\.004724658018144077\ \(0\)\
\-\ anemia\\:\\ 0\\.004713049038246854\ \(0\)\
\-\ arise\\:\\ 0\\.004690189518066437\ \(0\)\
\-\ \\Â\\»\\:\\ 0\\.004667791838113533\ \(0\)\
\-\ non\\-contrast\\:\\ 0\\.004624309894484618\ \(0\)\
\-\ almost\\:\\ 0\\.004582469176100087\ \(0\)\
\-\ fourth\\:\\ 0\\.004582469176100087\ \(0\)\
\-\ testing\\:\\ 0\\.004582469176100087\ \(0\)\
\-\ leading\\:\\ 0\\.004532295571235208\ \(0\)\
\-\ into\\:\\ 0\\.00450848418616343\ \(0\)\
\-\ therefore\\:\\ 0\\.0044749389477327815\ \(0\)\
\-\ received\\:\\ 0\\.004402806360873511\ \(0\)\
\-\ despite\\:\\ 0\\.004402806360873511\ \(0\)\
\-\ having\\:\\ 0\\.00435162893098087\ \(0\)\
\-\ incidence\\:\\ 0\\.004343324416868722\ \(0\)\
\-\ evaluated\\:\\ 0\\.004343324416868722\ \(0\)\
\-\ lack\\:\\ 0\\.004310714788036911\ \(0\)\
\-\ as\\:\\ 0\\.0042990382679405584\ \(0\)\
\-\ subsequently\\:\\ 0\\.004294762750950326\ \(0\)\
\-\ report\\:\\ 0\\.004240671659853395\ \(0\)\
\-\ clinic\\:\\ 0\\.004233155377164504\ \(0\)\
\-\ clinically\\:\\ 0\\.0041536743034881005\ \(0\)\
\-\ smooth\\:\\ 0\\.004146723513007396\ \(0\)\
\-\ per\\:\\ 0\\.004146723513007396\ \(0\)\
\-\ under\\:\\ 0\\.004139816029913565\ \(0\)\
\-\ development\\:\\ 0\\.004126128850509685\ \(0\)\
\-\ bleeding\\:\\ 0\\.004112608592090818\ \(0\)\
\-\ not\\:\\ 0\\.004106935715327944\ \(0\)\
\-\ have\\:\\ 0\\.004102966914335015\ \(0\)\
\-\ described\\:\\ 0\\.004034776819725797\ \(0\)\
\-\ compared\\:\\ 0\\.00401000154401405\ \(0\)\
\-\ of\\:\\ 0\\.004004010892170335\ \(0\)\
\-\ denies\\:\\ 0\\.003997818482400307\ \(0\)\
\-\ general\\:\\ 0\\.003991776791970635\ \(0\)\
\-\ adenoma\\:\\ 0\\.003956202163864758\ \(0\)\
\-\ an\\:\\ 0\\.0039301492160246\ \(0\)\
\-\ recommended\\:\\ 0\\.003927404507098394\ \(0\)\
\-\ views\\:\\ 0\\.003904893125545461\ \(0\)\
\-\ same\\:\\ 0\\.003904893125545461\ \(0\)\
\-\ family\\:\\ 0\\.003882829761557329\ \(0\)\
\-\ attenuation\\:\\ 0\\.0038088925392749874\ \(0\)\
\-\ shown\\:\\ 0\\.0037987213904101965\ \(0\)\
\-\ 15\\:\\ 0\\.0037786548253950993\ \(0\)\
\-\ complications\\:\\ 0\\.003754071834824897\ \(0\)\
\-\ use\\:\\ 0\\.003744389262797453\ \(0\)\
\-\ removal\\:\\ 0\\.0037347905236143992\ \(0\)\
\-\ matter\\:\\ 0\\.003730022140133922\ \(0\)\
\-\ minimal\\:\\ 0\\.003730022140133922\ \(0\)\
\-\ base\\:\\ 0\\.0037111510896134887\ \(0\)\
\-\ reveals\\:\\ 0\\.003706483093453463\ \(0\)\
\-\ change\\:\\ 0\\.0036925958874455024\ \(0\)\
\-\ rare\\:\\ 0\\.003678880486334031\ \(0\)\
\-\ second\\:\\ 0\\.0036387238749877805\ \(0\)\
\-\ used\\:\\ 0\\.0036343505065941925\ \(0\)\
\-\ based\\:\\ 0\\.0036127387608281157\ \(0\)\
\-\ 50\\:\\ 0\\.0036042106614676325\ \(0\)\
\-\ its\\:\\ 0\\.0035748685625894027\ \(0\)\
\-\ greater\\:\\ 0\\.003558443855510533\ \(0\)\
\-\ which\\:\\ 0\\.0035369059584091987\ \(0\)\
\-\ since\\:\\ 0\\.003479783394343921\ \(0\)\
\-\ abnormalities\\:\\ 0\\.003479783394343921\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.0034745329303678225\ \(0\)\
\-\ above\\:\\ 0\\.003472215805574076\ \(0\)\
\-\ early\\:\\ 0\\.003464699522885186\ \(0\)\
\-\ reported\\:\\ 0\\.003453519789995357\ \(0\)\
\-\ presence\\:\\ 0\\.003438786716693048\ \(0\)\
\-\ including\\:\\ 0\\.0034206415088613345\ \(0\)\
\-\ care\\:\\ 0\\.003417047834887752\ \(0\)\
\-\ weight\\:\\ 0\\.003395727034524241\ \(0\)\
\-\ identified\\:\\ 0\\.003385218449208782\ \(0\)\
\-\ location\\:\\ 0\\.0033045539766118548\ \(0\)\
\-\ inflammatory\\:\\ 0\\.003285272665401357\ \(0\)\
\-\ cause\\:\\ 0\\.0032053909385276786\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.0032024305964479904\ \(0\)\
\-\ although\\:\\ 0\\.003199478138111534\ \(0\)\
\-\ recent\\:\\ 0\\.00318483264838115\ \(0\)\
\-\ size\\:\\ 0\\.0031761373296882167\ \(0\)\
\-\ unremarkable\\:\\ 0\\.0031364372712661425\ \(0\)\
\-\ surrounding\\:\\ 0\\.0031143739072780102\ \(0\)\
\-\ body\\:\\ 0\\.003076789038457965\ \(0\)\
\-\ positive\\:\\ 0\\.003074152539117646\ \(0\)\
\-\ revealed\\:\\ 0\\.003040436684995669\ \(0\)\
\-\ any\\:\\ 0\\.0029831873980845827\ \(0\)\
\-\ will\\:\\ 0\\.0029639479139458337\ \(0\)\
\-\ approximately\\:\\ 0\\.0029310618919684956\ \(0\)\
\-\ medical\\:\\ 0\\.002914977605394683\ \(0\)\
\-\ some\\:\\ 0\\.002876860591870021\ \(0\)\
\-\ yo\\:\\ 0\\.002850722309648295\ \(0\)\
\-\ 6\\:\\ 0\\.0028294015092847832\ \(0\)\
\-\ there\\:\\ 0\\.002819768417882458\ \(0\)\
\-\ years\\:\\ 0\\.002781866005563728\ \(0\)\
\-\ demonstrated\\:\\ 0\\.002779844769907946\ \(0\)\
\-\ loss\\:\\ 0\\.0027499602798984916\ \(0\)\
\-\ level\\:\\ 0\\.0027304756404067983\ \(0\)\
\-\ two\\:\\ 0\\.0027132275361596517\ \(0\)\
\-\ when\\:\\ 0\\.0027132275361596517\ \(0\)\
\-\ axial\\:\\ 0\\.002703759951294758\ \(0\)\
\-\ include\\:\\ 0\\.0026575981020291427\ \(0\)\
\-\ performed\\:\\ 0\\.0026414393916045667\ \(0\)\
\-\ however\\:\\ 0\\.0026378803277129384\ \(0\)\
\-\ months\\:\\ 0\\.0025875180650665936\ \(0\)\
\-\ blood\\:\\ 0\\.002585821588147782\ \(0\)\
\-\ significant\\:\\ 0\\.0025475023847607798\ \(0\)\
\-\ due\\:\\ 0\\.002528023451167228\ \(0\)\
\-\ evidence\\:\\ 0\\.0024838609571694874\ \(0\)\
\-\ than\\:\\ 0\\.002482315803678796\ \(0\)\
\-\ prior\\:\\ 0\\.002432497530157831\ \(0\)\
\-\ both\\:\\ 0\\.002419290455306121\ \(0\)\
\-\ over\\:\\ 0\\.002412020609911267\ \(0\)\
\-\ more\\:\\ 0\\.002369375065756282\ \(0\)\
\-\ soft\\:\\ 0\\.0023070141507689026\ \(0\)\
\-\ tissue\\:\\ 0\\.0022454780359784854\ \(0\)\
\-\ man\\:\\ 0\\.0022405009346895778\ \(0\)\
\-\ without\\:\\ 0\\.0022306132664724615\ \(0\)\
\-\ other\\:\\ 0\\.002183634754659034\ \(0\)\
\-\ posterior\\:\\ 0\\.002183634754659034\ \(0\)\
\-\ were\\:\\ 0\\.002151093499656232\ \(0\)\
\-\ can\\:\\ 0\\.0021488052688127157\ \(0\)\
\-\ well\\:\\ 0\\.0021431052693665752\ \(0\)\
\-\ may\\:\\ 0\\.002077969366849361\ \(0\)\
\-\ had\\:\\ 0\\.00204417940048859\ \(0\)\
\-\ presents\\:\\ 0\\.001935304097015439\ \(0\)\
\-\ no\\:\\ 0\\.0019078584272811574\ \(0\)\
\-\ also\\:\\ 0\\.0018676492169292143\ \(0\)\
\-\ within\\:\\ 0\\.001807241029252862\ \(0\)\
\-\ on\\:\\ 0\\.0016050798500342085\ \(0\)\
\-\ \\(\\:\\ 0\\.001601688971715877\ \(0\)\
\-\ \\)\\:\\ 0\\.001582123485838814\ \(0\)\
\-\ disease\\:\\ 0\\.0015484895135429093\ \(0\)\
\-\ \\.\\:\\ 0\\.0014955458666287788\ \(0\)\
\-\ normal\\:\\ 0\\.0014851579319280499\ \(0\)\
\-\ mass\\:\\ 0\\.0013175842649086082\ \(0\)\
\-\ are\\:\\ 0\\.0012914344484807115\ \(0\)\
\-\ year\\:\\ 0\\.0010599836688169786\ \(0\)\
\-\ with\\:\\ 0\\.001037731051795031\ \(0\)\
\-\ old\\:\\ 0\\.0009699940098251159\ \(0\)\
